Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sumitomo Pharma Co (DNPUF) Fair Value & Analysis

Healthcare · US · Market cap $4.2B

Price$9.41
Fair Value$18.30
Upside+94.5%
Quality97/100
Evidence: High Range $13.73 – $22.88

Fair value as of: Jun 25, 2026

Analysis

Sumitomo Pharma Co (DNPUF) currently trades at $9.41, while our model-based Fair Value estimate is $18.30 — implying the stock looks roughly 94.5% undervalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Sumitomo Pharma Co (DNPUF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $18.30 versus a price of $9.41 — about +94% (undervalued). Model-based estimate, not financial advice.
What is the fair value of DNPUF?
Our 21-model fair value for Sumitomo Pharma Co is $18.30 (as of Jun 25, 2026), built from audited fundamentals. The current price is $9.41.
What is the quality score of DNPUF?
Sumitomo Pharma Co has a Quality Score of 97/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.